Table 1.
Clinical, laboratory, and CCTA characteristics of the study population
| Acute MI (n = 60) | Stable CAD (n = 60) | No CAD (n = 60) | P-value | |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Age (years) | 59.9 ± 11.6 | 60.2 ± 11.3 | 58.7 ± 12.8 | 0.82 |
| BMI (kg/m2) | 28.3 ± 5.9 | 28.7 ± 5.0 | 28.8 ± 5.4 | 0.93 |
| Male gender | 52 (86.7) | 52 (86.7) | 52 (86.7) | 1.00 |
| Hypertension | 44 (73.3) | 41 (68.3) | 42 (70.0) | 0.71 |
| Diabetes | 15 (25.0) | 13 (21.7) | 12 (20.0) | 0.65 |
| Dyslipidaemia | 32 (53.3) | 35 (58.3) | 31 (51.7) | 0.46 |
| Smoking | 24 (40.0) | 20 (33.3) | 19 (31.7) | 0.31 |
| Family history of CAD | 25 (41.7) | 27 (45.0) | 18 (30.0) | 0.34 |
| Baseline medications | ||||
| Antiplatelet | 11 (18.3) | 10 (16.7) | 8 (13.3) | 0.27 |
| Statin | 15 (25.0) | 17 (28.3) | 13 (21.7) | 0.35 |
| Beta-blocker | 10 (16.7) | 12 (20.0) | 10 (16.7) | 0.54 |
| ACE-I or ARB | 14 (23.3) | 14 (23.3) | 12 (20.0) | 0.46 |
| Lipids (mmol/L) | ||||
| Total cholesterol | 4.9 ± 1.3 | 5.1 ± 1.1 | 5.3 ± 1.2 | 0.08 |
| LDL cholesterol | 3.0 ± 1.1 | 3.0 ± 0.9 | 3.5 ± 1.1 | 0.06 |
| Inflammatory markers | ||||
| hs-CRP (mg/L) | 9.7 (6.2–13.3) | 1.8 (0–3.6) | 1.4 (0–2.8) | <0.001 |
| White cell count (×109/L) | 9.1 ± 3.0 | 6.5 ± 1.4 | 5.9 ± 2.2 | <0.001 |
| CCTA acquisition parameters | ||||
| Heart rate (bpm) | 53.9 ± 5.3 | 54.8 ± 8.4 | 56.4 ± 8.0 | 0.15 |
| Tube voltage | 1.00 | |||
| 100 kV | 22 (36.7) | 22 (36.7) | 22 (36.7) | |
| 120 kV | 38 (63.3) | 38 (63.3) | 38 (63.3) | |
| Contrast dose (mL) | 77.6 ± 11.0 | 76.2 ± 13.9 | 75.8.6 ± 9.8 | 0.65 |
| Radiation dose (DLP) | 284.8 ± 156.9 | 246.1 ± 171.4 | 275.2 ± 165.3 | 0.42 |
| Right coronary- or codominance | 56 (93.3) | 54 (90.0) | 55 (91.7) | 0.77 |
| CCTA segment scores | ||||
| Segment involvement score | 5.8 ± 3.1 | 5.1 ± 2.5 | 0.38 | |
| Segment stenosis score | 14.2 ± 7.9 | 9.7 ± 5.2 | 0.005 | |
| Quantitative plaque measures | ||||
| Proximal RCA plaque volume (mm2) | 140.7 ± 106.7 | 99.3 ± 68.0 | 0.13 | |
| Proximal RCA plaque burden (%) | 20.9 ± 14.2 | 12.9 ± 7.2 | 0.03 | |
| Total coronary plaque volume (mm2) | 554.0 ± 265.4 | 399.9 ± 187.5 | 0.09 | |
| Total coronary plaque burden (%) | 32.0 ± 15.5 | 18.4 ± 9.4 | <0.001 | |
| EAT measurements | ||||
| EAT volume (mm3) | 97.0 ± 25.6 | 85.4 ± 22.1 | 78.2 ± 28.8 | <0.001 |
| EAT attenuation (HU) | −87.2 ± 4.3 | −89.8 ± 4.7 | −90.2 ± 4.2 | 0.25 |
| PCAT attenuation (HU) | −82.3 ± 5.5 | −90.6 ± 5.7 | −95.8 ± 6.2 | <0.001 |
Values are expressed as n (%), mean ± standard deviations, or median (interquartile range, 25th–75th).
BMI, body mass index; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; HU, Hounsfield units; EAT, epicardial adipose tissue; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MI, myocardial infarction; RCA, right coronary artery. Bold face p-values indicate statistical significance.